What is ARAMIS?

Updated:Dec 7,2015
 
The Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in community practice. Building upon the existing infrastructure of the nation’s largest ongoing stroke registry (American Heart Association/American Stroke Association Get With The Guidelines-Stroke), the ARAMIS registry will be a multicenter, prospective, observational study of AIS and ICH patient on home anticoagulation therapy. Key data points will be abstracted from the medical records of approximately 15,000 patients from approximately 200 GWTG-Stroke hospitals over 3 to 5 years. Using an efficient study design, the ARAMIS registry will complement the results of both randomized controlled clinical trials and current GWTG-Stroke registry in addressing several key treatment management issues surrounding patients with either AIS or ICH on novel anticoagulant therapies. In particular, attention will be focused on coagulation tests, safety of thrombolytic therapy for AIS, treatment patterns of ICH, and clinical outcomes for AIS and ICH patients on novel oral anticoagulants. The acquisition of such findings would be critical important because it would help fill in gaps on guideline recommendations and provide insights into the management of AIS and ICH patients on treatment with new anticoagulants. This will allow physicians to feel more secure in their use of the novel agents while improving the care and outcomes of patients on these agents who have complications.
 
Objectives
  • Describe and characterize diagnostic tests being used to assess level of anticoagulation when a patient comes in with AIS or ICH on one of the novel agents
  • Examine the utilization and safety profile of thrombolytic therapy in AIS patients on new oral anticoagulants as compared with those on warfarin
  • Document current practice patterns for the care of ICH due to oral anticoagulants and determine how treatment and clinical outcomes vary by novel anticoagulants and warfarin therapy
The ARAMIS registry is designed as an efficient and scalable clinical research platform for stroke patients on oral anticoagulant therapy. In addition to standard ARAMIS data collection, optional Lab and Follow-up module will be available to selected sites for specialized anticoagulation assays in central core laboratory and longitudinal assessment of medication adherence and clinical outcomes. By building on this existing infrastructure, site start up, information burden and resources will be minimized, speeding up the registry start-up time while drastically reducing the total cost of ARAMIS registry.